# Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

> **NCT07131345** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Center, China** · enrollment: 55 (estimated)

## Conditions studied

- Malignant Mesothelioma
- Mesothelioma

## Interventions

- **DRUG:** iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy

## Key facts

- **NCT ID:** NCT07131345
- **Lead sponsor:** National Cancer Center, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-07-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131345, "Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07131345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*